Cancer Moonshot program for specific cancer types
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study is for people with certain cancers: lung, breast, gastric (stomach), pancreatic, or ovarian. It aims to test a Moonshot-style approach to improve cancer care for these groups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these cancers: lung, breast, gastric (stomach), pancreatic, or ovarian
- You must not have any other cancer type besides the study’s listed cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a combination treatment for advanced or metastatic stomach and food-pipe (gastroesophageal junction) cancer: a chemotherapy regimen (CapeOX) plus the immunotherapy drug sintilimab and the targeted drug bevacizumab. It aims to see how well this combination controls the cancer and how safely it can be given.
This study uses advanced testing (molecular profiling and imaging) to better understand cancers and help guide treatment. It is for people with certain advanced cancers who have not yet had immunotherapy or targeted therapy.
This trial tests a combination of chemotherapy (conversion therapy), surgery, and radiation for people with stomach cancer that has spread only to lymph nodes behind the stomach. The goal is to see if this approach can help shrink the cancer and improve outcomes.
This trial tests a new immunotherapy drug (SHR-1701) combined with chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal metastasis) but not to other organs like the liver or lungs. The goal is to see if this combination can help shrink or control the cancer before any surgery.
This trial is testing a new combination treatment for advanced or metastatic stomach cancer (that is MSS/pMMR and HER2-negative) that has not been treated before. The treatment combines a short course of radiation (targeted to lymph nodes) with first-line therapy and a PD-1 inhibitor (a type of immunotherapy) to see if it can help control the cancer and improve outcomes.
This study looks for specific genetic or molecular markers in advanced gastric cancer that has spread to other parts of the body. The goal is to identify which treatments might work best for each patient's individual cancer.
Hear when a new Malignant Neoplasm of Body of Stomach in Situ trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.